BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 35795530)

  • 1. An Integrative Analysis Revealing ZFHX4-AS1 as a Novel Prognostic Biomarker Correlated with Immune Infiltrates in Ovarian Cancer.
    Huang C; Cui H; Lang X; Zhao F
    J Immunol Res; 2022; 2022():9912732. PubMed ID: 35795530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PAXIP1-AS1 is associated with immune infiltration and predicts poor prognosis in ovarian cancer.
    Chen B; Lu X; Zhou Q; Chen Q; Zhu S; Li G; Liu H
    PLoS One; 2023; 18(8):e0290031. PubMed ID: 37582104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Downregulation of LEMD1-AS1 and Its Influences on the Diagnosis, Prognosis, and Immune Infiltrates of Epithelial Ovarian Cancer.
    Yang X; Zhou S; Li C; Huang L; Chen C; Tang X; Su X; Zhu H
    Dis Markers; 2022; 2022():6408879. PubMed ID: 35968498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel LncRNA ZFHX4-AS1 as a Potential Prognostic Biomarker That Affects the Immune Microenvironment in Ovarian Cancer.
    Wang X; Wang Y; Sun F; Xu Y; Zhang Z; Yang C; Zhang L; Lou G
    Front Oncol; 2022; 12():945518. PubMed ID: 35903691
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TBX5-AS1, an enhancer RNA, is a potential novel prognostic biomarker for lung adenocarcinoma.
    Cheng L; Han T; Chen B; Nie K; Peng W
    BMC Cancer; 2021 Jul; 21(1):794. PubMed ID: 34238250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A prognostic model based on immune-related long noncoding RNAs for patients with epithelial ovarian cancer.
    Peng Y; Wang H; Huang Q; Wu J; Zhang M
    J Ovarian Res; 2022 Jan; 15(1):8. PubMed ID: 35031063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Down-regulated long non-coding RNA RNAZFHX4-AS1 suppresses invasion and migration of breast cancer cells via FAT4-dependent Hippo signaling pathway.
    Li SY; Wang H; Mai HF; Li GF; Chen SJ; Li GS; Liang BC
    Cancer Gene Ther; 2019 Nov; 26(11-12):374-387. PubMed ID: 30546116
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical significance of lncRNA FAM83H-AS1 in ovarian cancer.
    Gong YB; Zou YF
    Eur Rev Med Pharmacol Sci; 2019 Jun; 23(11):4656-4662. PubMed ID: 31210291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic Role of Zinc Finger Homeobox 4 in Ovarian Serous Cystadenocarcinoma.
    Ha M; Kim J; Park SM; Hong CM; Han ME; Song P; Kang CD; Lee D; Kim YH; Hur J; Oh SO
    Genet Test Mol Biomarkers; 2020 Mar; 24(3):145-149. PubMed ID: 32105524
    [No Abstract]   [Full Text] [Related]  

  • 10. A bioinformatics analysis: ZFHX4 is associated with metastasis and poor survival in ovarian cancer.
    Zong S; Xu PP; Xu YH; Guo Y
    J Ovarian Res; 2022 Aug; 15(1):90. PubMed ID: 35915456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FOXP4-AS1 is a favorable prognostic-related enhancer RNA in ovarian cancer.
    Hua T; Tian YJ; Wang RM; Zhao CF; Kong YH; Tian RQ; Wang W; Ma LX
    Biosci Rep; 2021 Apr; 41(4):. PubMed ID: 33870423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive Analysis of Enhancer RNAs Identifies LINC00689 and ELFN1-AS1 as Novel Prognostic Biomarkers in Uveal Melanoma.
    Zhao S; Jiang H; Liu J; Li DY; Li B; Long QR; Zheng L; Gu H
    Dis Markers; 2022; 2022():5994800. PubMed ID: 35251374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. METTL3-mediated m6A modification of lnc RNA RHPN1-AS1 enhances cisplatin resistance in ovarian cancer by activating PI3K/AKT pathway.
    Cui S
    J Clin Lab Anal; 2022 Dec; 36(12):e24761. PubMed ID: 36336887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SPRY4-AS1, A Novel Enhancer RNA, Is a Potential Novel Prognostic Biomarker and Therapeutic Target for Hepatocellular Carcinoma.
    Ye M; Wang S; Qie JB; Sun PL
    Front Oncol; 2021; 11():765484. PubMed ID: 34671565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LncRNA PSMA3-AS1 promotes cell proliferation, migration, and invasion in ovarian cancer by activating the PI3K/Akt pathway via the miR-378a-3p/GALNT3 axis.
    Xu Z; Jin H; Duan X; Liu H; Zhao X; Fan S; Wang Y; Yao T
    Environ Toxicol; 2021 Dec; 36(12):2562-2577. PubMed ID: 34520102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum lncRNA LOXL1-AS1 is a diagnostic and prognostic marker for epithelial ovarian cancer.
    Liu CN; Zhang HY
    J Gene Med; 2020 Oct; 22(10):e3233. PubMed ID: 32449981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Down-regulation of long noncoding RNA DLX6-AS1 defines good prognosis and inhibits proliferation and metastasis in human epithelial ovarian cancer cells via Notch signaling pathway.
    Zhao J; Liu HR
    Eur Rev Med Pharmacol Sci; 2019 Apr; 23(8):3243-3252. PubMed ID: 31081076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LncRNA MNX1-AS1 promotes ovarian cancer process via targeting the miR-744-5p/SOX12 axis.
    Shen Y; Lv M; Fang Y; Lu J; Wu Y
    J Ovarian Res; 2021 Nov; 14(1):161. PubMed ID: 34789303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CYP1B1-AS1 Is a Novel Biomarker in Glioblastoma by Comprehensive Analysis.
    Ye T; Li LL; Peng XM; Li Q
    Dis Markers; 2021; 2021():8565943. PubMed ID: 35003394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overexpression of lncRNA MNX1-AS1 is associated with poor clinical outcome in epithelial ovarian cancer.
    Li AH; Zhang HH
    Eur Rev Med Pharmacol Sci; 2017 Dec; 21(24):5618-5623. PubMed ID: 29271994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.